Cargando…

In vitro activity of tigecycline against clinical isolates of carbapenem resistant Acinetobacter baumannii complex in Pretoria, South Africa

BACKGROUND: The presence of multi-drug resistant Acinetobacter baumannii raises a big therapeutic challenge in our hospital. Tigecycline, a new glycylcycline with expanded broad spectrum of activity against multi-drug resistant organisms was recently licensed in South Africa. AIM: The aim of this st...

Descripción completa

Detalles Bibliográficos
Autores principales: Ahmed, Nahid H, Baba, Kamaldeen, Clay, Cornelis, Lekalakala, Ruth, Hoosen, Anwar A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3422175/
https://www.ncbi.nlm.nih.gov/pubmed/22554305
http://dx.doi.org/10.1186/1756-0500-5-215
_version_ 1782241004935446528
author Ahmed, Nahid H
Baba, Kamaldeen
Clay, Cornelis
Lekalakala, Ruth
Hoosen, Anwar A
author_facet Ahmed, Nahid H
Baba, Kamaldeen
Clay, Cornelis
Lekalakala, Ruth
Hoosen, Anwar A
author_sort Ahmed, Nahid H
collection PubMed
description BACKGROUND: The presence of multi-drug resistant Acinetobacter baumannii raises a big therapeutic challenge in our hospital. Tigecycline, a new glycylcycline with expanded broad spectrum of activity against multi-drug resistant organisms was recently licensed in South Africa. AIM: The aim of this study was to evaluate the in vitro activity of tigecycline against carbapenem resistant A. baumannii complex. METHODS: Consecutive clinical isolates of carbapenem resistant A. baumannii complex were collected between February and July 2010. Species identification and susceptibility testing was performed by Vitek-2 colorimetric compact system with Advanced Expert System (AES). Strains were tested for carbapenemase production by the modified Hodge test, according to the Clinical and Laboratory Standards Institute (CLSI) guidelines. RESULTS: A total of 232 carbapenem resistant clinical isolates of A. baumannii complex were collected over the six months study period; 217 (93.5%) of these were modified Hodge test positive. All isolates were susceptible to colistin and 174 (78%) susceptible to amikacin whilst 20 (9%) were susceptible to ciprofloxacin. For tigecycline 169 (75.8%) were fully susceptible, 37 (16.6%) intermediately resistant and only 17 (7.6%) were fully resistant. None of the carbapenem resistant isolates were susceptible to ampicillin, amoxicillin/clavullanic acid, piperacillin/tazobactam, cefuroxime, cefuroxime axetil, cefoxitin, cefepime or nitrofurantoin. CONCLUSION: All carbapenem resistant isolates were found to be fully susceptible to colistin; amikacin and tigecycline susceptibility was 78% and 76% respectively. Treatment options for infections due to carbapenem and multi-drug resistant A. baumannii organisms are limited and hence tigecycline and amikacin may be considered. The properties of tigecycline i.e. stability, safety, low toxicity, non cross-resistance with other antibiotics and its efficacy against multi-drug resistant A. baumannii isolates make it a good choice. However, ongoing monitoring of A. baumannii susceptibility to tigecycline is needed.
format Online
Article
Text
id pubmed-3422175
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-34221752012-08-18 In vitro activity of tigecycline against clinical isolates of carbapenem resistant Acinetobacter baumannii complex in Pretoria, South Africa Ahmed, Nahid H Baba, Kamaldeen Clay, Cornelis Lekalakala, Ruth Hoosen, Anwar A BMC Res Notes Research Article BACKGROUND: The presence of multi-drug resistant Acinetobacter baumannii raises a big therapeutic challenge in our hospital. Tigecycline, a new glycylcycline with expanded broad spectrum of activity against multi-drug resistant organisms was recently licensed in South Africa. AIM: The aim of this study was to evaluate the in vitro activity of tigecycline against carbapenem resistant A. baumannii complex. METHODS: Consecutive clinical isolates of carbapenem resistant A. baumannii complex were collected between February and July 2010. Species identification and susceptibility testing was performed by Vitek-2 colorimetric compact system with Advanced Expert System (AES). Strains were tested for carbapenemase production by the modified Hodge test, according to the Clinical and Laboratory Standards Institute (CLSI) guidelines. RESULTS: A total of 232 carbapenem resistant clinical isolates of A. baumannii complex were collected over the six months study period; 217 (93.5%) of these were modified Hodge test positive. All isolates were susceptible to colistin and 174 (78%) susceptible to amikacin whilst 20 (9%) were susceptible to ciprofloxacin. For tigecycline 169 (75.8%) were fully susceptible, 37 (16.6%) intermediately resistant and only 17 (7.6%) were fully resistant. None of the carbapenem resistant isolates were susceptible to ampicillin, amoxicillin/clavullanic acid, piperacillin/tazobactam, cefuroxime, cefuroxime axetil, cefoxitin, cefepime or nitrofurantoin. CONCLUSION: All carbapenem resistant isolates were found to be fully susceptible to colistin; amikacin and tigecycline susceptibility was 78% and 76% respectively. Treatment options for infections due to carbapenem and multi-drug resistant A. baumannii organisms are limited and hence tigecycline and amikacin may be considered. The properties of tigecycline i.e. stability, safety, low toxicity, non cross-resistance with other antibiotics and its efficacy against multi-drug resistant A. baumannii isolates make it a good choice. However, ongoing monitoring of A. baumannii susceptibility to tigecycline is needed. BioMed Central 2012-05-03 /pmc/articles/PMC3422175/ /pubmed/22554305 http://dx.doi.org/10.1186/1756-0500-5-215 Text en Copyright ©2012 Ahmed et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Ahmed, Nahid H
Baba, Kamaldeen
Clay, Cornelis
Lekalakala, Ruth
Hoosen, Anwar A
In vitro activity of tigecycline against clinical isolates of carbapenem resistant Acinetobacter baumannii complex in Pretoria, South Africa
title In vitro activity of tigecycline against clinical isolates of carbapenem resistant Acinetobacter baumannii complex in Pretoria, South Africa
title_full In vitro activity of tigecycline against clinical isolates of carbapenem resistant Acinetobacter baumannii complex in Pretoria, South Africa
title_fullStr In vitro activity of tigecycline against clinical isolates of carbapenem resistant Acinetobacter baumannii complex in Pretoria, South Africa
title_full_unstemmed In vitro activity of tigecycline against clinical isolates of carbapenem resistant Acinetobacter baumannii complex in Pretoria, South Africa
title_short In vitro activity of tigecycline against clinical isolates of carbapenem resistant Acinetobacter baumannii complex in Pretoria, South Africa
title_sort in vitro activity of tigecycline against clinical isolates of carbapenem resistant acinetobacter baumannii complex in pretoria, south africa
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3422175/
https://www.ncbi.nlm.nih.gov/pubmed/22554305
http://dx.doi.org/10.1186/1756-0500-5-215
work_keys_str_mv AT ahmednahidh invitroactivityoftigecyclineagainstclinicalisolatesofcarbapenemresistantacinetobacterbaumanniicomplexinpretoriasouthafrica
AT babakamaldeen invitroactivityoftigecyclineagainstclinicalisolatesofcarbapenemresistantacinetobacterbaumanniicomplexinpretoriasouthafrica
AT claycornelis invitroactivityoftigecyclineagainstclinicalisolatesofcarbapenemresistantacinetobacterbaumanniicomplexinpretoriasouthafrica
AT lekalakalaruth invitroactivityoftigecyclineagainstclinicalisolatesofcarbapenemresistantacinetobacterbaumanniicomplexinpretoriasouthafrica
AT hoosenanwara invitroactivityoftigecyclineagainstclinicalisolatesofcarbapenemresistantacinetobacterbaumanniicomplexinpretoriasouthafrica